SITE010-0181

SITE010 (ESP) › SITE010-0181

SITE010-0181

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE010 (ESP) · Dr. Silva
consented 2026-03-31

enrolled

AEs

2

Serious

0

Dropout signal

–

Adverse events

2

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-02-27 (study day 139); relationship: NOT RELATED

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-11-29 (study day 49); relationship: NOT RELATED

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.